Friday, June 5, 2009

Merck Misses on PROTECT; Schering-Plough (and Merck) Shares Fall on NYSE. . . .


The study was called PROTECT -- and even when compared to a placebo -- Merck's drug candidate rolofylline, um. . . didn't.

Per Yahoo! News:

. . . .Merck said its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo. . . .

The medicine failed to meet the primary or secondary efficacy goals in the 2,033-patient Phase III study. . . .

The Whitehouse Station, N.J., company says rolofylline did not reach its primary or secondary goals in the late-stage trial. . . .

And so it goes -- being joined at the hip is not always a good thing.

No comments: